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 Neurodegenerative diseases are often associated with issues in protein degradation 
brought on by protein aggregates and misfolded proteins that yield proteotoxicity. 
Amyotrophic Lateral Sclerosis (ALS) serves as the main focus for our lab, as we perform 
experiments in vitro and in vivo to try and reduce aggregation of mutant super oxide 
dismutase 1 (SOD1). Two approaches used for undertaking study of protein degradation: a 
small molecule SIRT2 inhibitor drug trial in G93A mice to test motor skills and survival, and 
a series of experiments inducing DNA damage and proteotoxicity to discern fluctuations in 
UBE4B and LSD1. Through 15-17 weeks of drug injections in both male and female 
cohorts, there was a small improvement in overall lifespan with the drug that was not 
statistically significant, and no significant differences between the drug and control groups in 
motor ability. Following inducing stress through various means, there were consistent 
patterns of reductions in key ubiquitin ligases and associated proteins across four cell lines: 
H293T, HCT P53 +/+, HCT P53 -/-, and NSC34. These findings offer affirmation in the 
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Introduction 
  Environmental stressors and inevitable gene replication errors present challenges to 
the structure and integrity of macromolecules, such as DNA and proteins, which are 
remedied by different internal mechanisms. Errors in the integrity of proteins yielding 
misfolded products or aggregates – termed proteotoxicity – are a common feature among 
neurodegenerative disease; including Alzheimers disease, Parkinsons disease, Huntingtons 
disease, and Amyotrophic Lateral Sclerosis (ALS) (Prusiner, 2012). Amyotrophic Lateral 
Sclerosis (ALS), which is characterized by a loss of upper and lower motor neuron function 
in the brain and spinal cord, has been an active area of research in the past 25 years. One 
major mutation that is believed to cause ALS is in the TDP-43 gene, with reports of 19 
missense and 1 truncating mutation occurring in TDP-43 that have been correlated with 
ALS patients (Strong et al., 2007). Mutation of the TDP-43 gene is believed to be an impetus 
in the formation of a mutant form of Superoxide Dismutatse 1 (SOD1) that is prone to 
aggregation – a characteristic that induces a high level of proteotoxicity that is believed to 
lead to the decline of motor neuron function (Arai et al., 2006). The internal mechanisms in 
place to combat proteotoxicity, specifically the aggregation associated with ALS, represent a 
complex set of effectors regulated by protein-protein interactions, components of which 
serve as the objective for this study.  
 
Protein Quality Control and Mutant SOD1 in ALS 
 With estimates suggesting that 30% of newly synthesized proteins are incorrectly 
folded and promptly degraded, understanding the mechanisms behind these controls serves 
as an important stepping stone in discerning patterns behind pathologies involving 
proteotoxicity (Shubert et al., 2000). As with other biological systems aimed at maintaining 
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homeostasis, the protein quality control systems have two major lines of defense against 
misfolded or aggregating proteins – molecular chaperones for disposal, the Ubiquitin-
Proteasome Pathway (UPS) (Cookson, 2005).  
 Molecular chaperones, which represent the first line of defense against 
proteotoxicity, facilitate the efficient folding and reverse unfolding of proteins (Hershko & 
Ciechanover, 1998). They work effectively by binding to the aggregation-prone sections of 
proteins – often hydrophobic stretches – and change local conformation by non-covalent 
interactions to stabilize them against irreversible aggregation (Kopito, 2000). An important 
class of chaperones is the Heat Shock Proteins (HSPs), which are ubiquitous elements of 
cellular machinery that offset a variety of stresses (Uversky, 2009). For example, the 
characteristic poly-glutamine induced toxicity of Huntington’s disease is mitigated by the 
protective effects of HSP70 (Klucken et al., 2004).   
 The Ubiquitin-Proteasome Pathway (UPS), widely considered the second line of 
defense against proteotoxicity, selectively conjugates and targets abnormally structured 
proteins for degradation via covalent modification (polyubiquitination) (Morimoto et al., 
1989). In order to function this way the system requires certain ligases that receive ubiquitin 
from E2 ligases and transfers it to targeted proteins by creating multi-ubiquitin chains (Wu & 
Leung, 2011). Special features of the UPS include differing signals for protein degradation: 
K-48 linked polyubiquitination serve as the classical sign for proteasomal degradation as it 
leads the ubiquitinated protein to be recognized by the 26S Proteasome (Navon, 2009). K-63 
linked polyubiqutination serves as signal for autophagy into the Autophagy – Lysosome 
Pathway (ALP), which leads to degradation by engulfing the protein within a double 
membrane that forms an autophagosome (Bence et al., 2001).   
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 Cu/Zn Superoxide dismutase 1 (SOD1) normally serves a protective role as it 
destroys free radicals and superoxides. However, mutant Cu/Zn SOD1 has been linked to 
roughly 20% of familial ALS cases, and is characterized by a tendency to misfold and 
aggregate in motor neurons (Wang et al., 2002). The wild type (WT) SOD1 is characterized 
by a stable β-barrel structure with a two-state folding process, however mutant SOD1 has a 
far higher propensity to improperly fold and aggregate in vitro and in vivo (Lindberg et al., 
2005). Here we used the G85R mutant human SOD1 (SOD1G85R), which clinically leads to 
aggregation into misfolded soluble oligomers, and larger insoluble aggregates – highly toxic 
proteins that lead to age-dependent synaptic dysfunction, neurodegeneration, and impaired 
motor abilities in C. elegans and mice (Wang et al., 2009).  
 
Effects of UBE4B, LSD1, and USP7 on P53-mediated Protein Quality Control Measures 
Within the protein quality control mechanisms in place to deal with proteotoxicity, 
there are several notable contributors to chaperone proteins, the UPS system, and the ALP 
pathway. The UPS system is made up of several classes of enzymes that facilitate its 
functionality in tagging targets: E1 refers to ubiquitin-activating enzymes, E2 refers to 
ubiquitin conjugating enzymes, and E3 refers to ubiquitin protein ligases (Johnson et al., 
1997). A newer addition to the family is the E4 class, which is necessary for the degradation 
of certain proteins via the ubiquitin fusion degradation pathways. E4 enzymes specifically 
catalyze the elongation of a polyubiquitin chain, thereby allowing targeting of 
polyubiqutinated substrate proteins for degradation by the proteasome (Kuhlbrodt et al., 
2005).  
One E4 enzyme of particular focus is ubiquitin factor E4B (UBE4B), which is 
located in the 1p36 region and has been tied across several studies to p53 (Hatakeyama et al., 
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2001). Recently, studies have shown that UBE4B promotes polyubiqtuitination and 
degradation of p53, while also inhibiting p53-dependent transactivation and apoptosis (Wu 
et al., 2011) (Shi et al., 2009). In a molecular context, UBE4B is amplified to abnormal levels 
in a variety of cancers: including colon cancer, breast cancer, and promyelocytic leukemia 
(Heuze et al., 2008; Hosada et al., 2005). Further results from studies showed that deletion of 
UBE4B from cancer cell lines resulted in the marked apoptosis of tumor cells, suggesting 
that reducing UBE4B may lead more efficient greater protein quality control machinery. The 
most recent studies have suggested that one of the central targets for UBE4B is actually p53, 
which seems to support the notion that UBE4B’s inhibition leading to a more active protein 
quality control mechanism rests heavily on p53’s activity (Zeinab et al., 2012). 
 Another route for impacting p53-mediated protein quality control machinery is 
through genetic/epigenetic modifications. While methylation of lysines on histone tails 
produces a silencing effect, these residues can be demethylated by variety of lysine-specific 
demethylases (LSDs) (Anand & Marmorstein, 2007). LSD1 was the first histone demethylase 
discovered, and it was primarily participated in gene repression as a component of CoREST 
(Co-repressor for Element-1 Silencing Transcription Factor) and NuRD (Nucleosome 
Remodeling and Histone Deacetylation) co-repressor complexes (Shi et al., 2007). LSD1 
works by removing methyl groups from mono- and di-methylated lysine-4 residues of 
histone H3, one of the five main euchromatin histone proteins, and can catalyze de-
methylation of histone H3 lysine-9 in cooperation with the androgen receptor (Wang et al., 
2009; Chen et al., 2006). Lys-4 and lys-9 demethylations make LSD1 a significant component 
of transcriptional co-repressor complexes, and the demethylase been found to play an 
important role in silencing neuron-specific genes in non-neuronal cells (Schulte et al., 2009; 
Forneris et al., 2006).  LSD1’s interactions with H3 lysine-9 include gene activation via 
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demethylation of several non-histone substrates, including p53 (Metzger et al., 2005). More 
recently within this lab results have shown that a knockdown of LSD1 and UBE4B in wild 
type SOD1 and mutant SOD1G85R transfected HEK293T cells result in a reduction of mutant 
misfolded proteins. Additionally, in agreement with previous studies in C. elegans and 
Drosophila, the knockdown of UBE4B/LSD1 enhanced protein clearance beyond mutant 
SOD1G85R to include reductions in other aggregation-prone proteins, including TDP-43Q331K, 
suggesting a more centralized effect on protein quality control (Periz et al., 2015).   
 Stabilization of P53 represents another option for enhancing protein quality control 
measures that are driven by the “guardian of the genome”.  P53 is kept in an autoregulatory 
feedback loop by Mouse double minute-2 homolog (MDM2) – an E3 ubiquitin ligase 
protein – by polyubiquitinating  p53 in the absence of detected DNA damage (Chen et al., 
1996). The process of stabilizing p53, however, can be achieved by deubituitinating the 
protein – a task a special class of enzymes are capable of: Deubiquititylating enzyme 
ubiquitin specific peptidases (USPs) (Li et al., 2004). One such ubiquitin specific peptidase is 
USP7 – a herpes virus-associated ubiquitin-specific protease (also called HAUSP) that acts as 
a cysteine protease, and was originally identified as a binding partner for the Herpes Simplex 
Virus (Everett et al., 1997). Crystallography analysis demonstrated that MDM2 and p53 both 
bind the N-terminal tumor necrosis factor-receptor associated factor (TRAF)-like domain of 
USP7 in a mutually exclusive manner, but USP7 retains a higher affinity for MDM2 than p53 
(Hu et al., 2006). Further cell culture studies have illustrated that a genetic blockade of USP7 
results in a destabilization of the autoregulatory feedback loop of MDM2/p53, and led to an 
up-regulation of p53 with concomitant cell cycle arrest (Cummins et al., 2004). These 
findings together suggest that USP7’s ability to inactivate MDM2 and elevate P53 activity 
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may factor into greater protein quality control mechanisms in place to deal with the types of 
protein aggregates that are characteristic of ALS.  
 
Experimental Pursuits with p53 Activation and Proposed Protein Quality Control Pathways 
 The experiments associated with this study examined the issue of proteotoxicity in 
ALS from two different standpoints – in vivo and in vitro. The in vivo aspect of this study 
dealt with the use of Tenovin-1, a SIRT1/2 inhibitor that increases acetylation and stability 
of p53, in cohorts of litter-matched male and female cohorts of G93A mice (Lain et al., 
2008). Through a 15-week drug or control injection period, the mice were observed for 
changes in mass, motor skills, grip strength, and overall survival. Building from experiments 
in cell culture where Tenovin-1 was shown to reduce SOD1G85R protein aggregates, it was 
hypothesized that the elevated p53 levels would reduce mutant SOD1 aggregates and extend 
motor abilities, improve weight retention, and extend overall survival beyond the control.  
 The in vitro aspect of this study sought to examine the actors involved in protein 
quality control mechanisms mediated by p53. Aforementioned studies indicate that 
inhibiting UBE4B, USP7, and LSD1 result in a more robust reduction of mutant SOD1 
aggregates, which has been replicated by experiments in this laboratory using tumor cells in 
cell culture, C. elegans, and Drosophila as model organisms. The latest findings in this 
laboratory also implicate a synergistic relationship between UBE4B and LSD1 in a 
hypothesized protein quality control pathway (the SUNS pathway) mediated by p53 that 
suppresses proteotoxicity-associated neurodegeneration (Periz et al., 2015). In order to 
understand potential mechanisms involved with the pathway, experiments imparting 
different types of proteotoxic stresses on cells were devised to test levels of these proteins 
tested against controls. Through the use of doxorubicin damage (DNA intercalation), 
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transfection with WT SOD1 and SOD1G85R (protein aggregates), and heat shock as methods 
of stressors, the effects were observed in cell lines via western blot. 
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Methods and Materials 
Cell Culture 
 For the cell culture experiments performed, four lines of cells were used. Human 
Embryonic Kidney 293T cells (HEK293T) were used as controls due to availability of high 
yield transfections protocols and robust growth potential. Human Colon Cancer P53 wild 
type cells (HCT+/+) and Human Colon Cancer P53 Knockout cells (HCT-/-) were used to 
contrast the impact of P53 against its absence on protein quality control mechanisms as 
stressors were applied, including protein aggregation. Mouse Motor Neuron-like hybrid cells 
(NSC34) were used to analyze whether the results found from the other cell lines could be 
replicated in motor neuron-like cells, which are most affected by protein aggregation in the 
pathology of Amyotrophic Lateral Sclerosis. The cell lines were kept in 10% Fetal Bovine 
Serum (FBS) Dulbecco’s Modified Eagle Medium (DMEM), with added non-essential amino 
acids, β-mercaptoethanol, and glutamax. 
 
Heat Shock 
 The four cell lines used (HEK293T, HCT +/+, HCT -/-, NSC34) were plated in 60 
mm dishes pre-treated with Polyethylenimine (PEI) for one hour. The cell concentrations 
used were 2 ml of 3 x 105 cells/ml in DMEM. The dishes were made in duplicates; one was 
for extracting protein while the other was to extract RNA. The dishes were divided into 
three groups: control plates were kept at 37˚C, 1 hour heat shock plates kept at 43˚C, and 2 
hour heat shock plates were kept at 43˚C for two hours. Immediately following the end of 
heat shock treatment, the cells were placed on ice and lysed with RIPA lysis buffer for 




 The four cell lines used (HEK293T, HCT +/+, HCT -/-, NSC34) were plated in 6 
well dishes pre-treated with PEI for an hour. The cell concentrations used were 2 ml of 7.5x 
104 cells/ml. The dishes, made in duplicates for RNA and protein extraction separately, were 
left to incubate overnight before transfection via lipofectamine 3000. They were transfected 
with either wild type (WT) Superoxide Dismutase 1 (SOD1) or G85R. After confirming high 




Doxorubicin DNA Damage 
The three cell lines used (HEK293T, HCT -/-, NSC34) were plated in 6 well dishes 
pre-treated with PEI for one hour. The cell concentrations used were 2 ml of 1.5 x 105 
cells/ml. The dishes were divided into control and experimental, and made in duplicates to 
allow for both protein and RNA extraction. The experimental cells were treated with 16 ml 
of DMEM mixed with 4µl of Doxorubicin – an agent that intercalates DNA and is often 
used in chemotherapy – in order to induce a stress on the cells.  
 
Rotarod 
 We obtained the Rotarod Machine (LE8200) from Harvard Apparatus (Holliston, 
MA). Mice were trained on the rotarod at increasing speeds from 6 rpm up to 16 rpm for 5 
minutes at three separate times, in one-hour intervals in a day, the day before testing and 
injections. Mice that fell off during training were put back onto the rotating rod for the 
continued duration of five minutes. In testing, mice were placed on the rod in an accelerating 
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speed, over the course of 5 minutes, as it rose from 4 rpm to 40 rpm. Once the mice fell 
from the rod, their times were recorded and they were placed back into their cages. Before 
and after each run, the rod and rip plates were wiped down with 70% ethanol. During the 
course of the drug trial, both control and experimental groups of mice underwent training 
once a week and testing twice a week, with injections only occurring after testing. The 
training and testing was concluded for mice that were no longer able to stay on the rod for 




 In the drug trial, intraperitoneal (IP) injections of SOD G93A mice with either the 
Tenovin-1 drug or a control solution began once the mice reached 60-64 days old (average 
63 days). IP injections were administered twice a week for 15 weeks. Tenovin-1, a P53 
activator (Tocris), was dissolved in a 70% 2-hydroxypropyl-β-cyclodextrin (Sigma-Aldrich, 
St. Louis, MO) water solution to make for a total drug concentration injected of 40.9 mg/kg, 
which came out to 1.818 mg/ml of solution we injected. The 250 µl of the 1.818 mg/ml 
solution of Tenovin-1 and 70% Cyclodextrin was combined with 400 µl of Phosphate Buffer 
Saline (PBS) and mixed, then 400 µl was injected into each mouse in the drug group. For the 
control group, the 400 µl injection was composed of a mixture of 250 µl of 70% 
Cyclodextrin and 400 µl of PBS.   
 
Grip Test 
 We utilized the Bioseb Grip Test (Vitrolles, France) in order to obtain additional data 
on the grip strength of mice using the slanted mesh attachment. Following previous 
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literature on strategies to use the test that detailed forelimb and hind-limb strength, we opted 
for measuring total limb strength by holding the mouse by its tail and lowering it onto the 
mesh until all limbs had grasped the slanted mesh. Then we would pull the mouse by the tail 
perpendicular to the slanted mesh, three times, and average the trials for data points. Data 
from the Grip test was not presented because of issues in reproducibility, consistency, and a 




 For the purposes of the drug trial, the disease endpoint was defined by the mouse 
not being able to right itself after ten seconds of being placed on its back (Dardiotis et al., 
2013). This was discerned by testing the mice three times when they had visible trouble 
moving or performing on the rotarod, and if two of the three tests showed they could not 
right themselves within ten seconds they were deemed to be at the endpoint.  
 
Tissue Harvesting 
 Mice in the trial, from both drug and control groups that had reached the disease 
endpoint were removed from their cages and euthanized with carbon dioxide. Immediately 
following euthanization, the brain, spinal cord (dissected into left and right), and muscle 
taken from the legs were all removed and immediately dry-frozen in liquid nitrogen. These 




Tenovin-1 Drug Trial in G93A Mice 
Following successful knockdown of mutant G85R SOD aggregates in vitro, 
Tenovin-1 was used to launch a drug trial in the transgenic G93A line of mice. The dosing 
of the drug was based on a previous chemotherapeutic use in literature, where a dosage of 92 
mg/kg was used, followed by dilutions to sustain mouse survival for longer periods of time. 
Following an optimization process in which various concentrations were formulated, the 
ultimate planned dosage cut the chemotherapeutic use’s concentration in half to 46 mg/kg – 
which resulted in use of a 40.9 mg/kg dosage once mixed.  
 In the design of the study, the G93A positive males and females were divided, then 
the gender groups were further divided into a drug and control cohort where the groups 
were matched by litter. Thus, each pair of G93A positive mice was split so one would go 
enter the control group and the other the drug group. The mice in the drug and control 
groups were assigned randomly. They were then kept in cages with their littermates until 
they reached 60-64 days of age, when they began training and testing on the Rotarod 
machine and injections. The mice were first trained on the machine for five minutes, and 
then tested the following day. Data points consisted of three trials of testing on the Rotarod 
machine, each one hour apart, and a mass measurement following the third trial. The mice 
were then injected and released back into their cage. Mice were trained and tested once a 
week, and injected twice a week for up to fifteen weeks if they survived. The total number of 
mice in the female cohort for which data is presented is 32 (16 drug and 16 control) while 
the total number of mice in the male cohort for which data is presented is 10 (5 in the drug 
group and 5 in the control group).   
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Figure 1: A+B: Drug group in both female and male cohorts demonstrated longer survival 
over control groups, but difference was not significant at p<.05. Death was measured by 
discovery of dead body (checked daily) or failure of survival test (inability to correct self in 10 
seconds when turned over). 
 
C+D:  Differences in mass for both drug and control groups in both cohorts were not 
significant at p<.05. Mass retention was used as a proxy for overall health, and was used as a 
prognostic indicator for when symptoms began. Mass was measured following Rotarod testing 
each week.  
 14 
Drug Treatment Offered Small but Non-Significant Improvement in Lifespan and Mass Retention 
  
The results of long term survivorship and mass retention can be seen in Figure 1, 
with slight differences between the female and male cohorts. In the female cohort, consisting 
of 32 mice, it can be seen that the average age at death for the drug group was 172.67 days 
while the control group’s value was 168.78 – a difference that was not found to be 
significant by T-Test at p<.05. Furthermore, the female drug group shows a consistently 
higher average mass than the control group through the duration of the 17 weeks of data 
collection. In the male cohort, consisting of 10 mice, the average age at death for the drug 
group was 168.5 days while it was 165.5 days for the control group – a slight difference that 
was also found to be not significant by T-Test at p<.05. Unlike the female cohort, the male 
cohort’s control group held a higher average mass than the drug group for the duration of 
the 15 weeks of data collection. It is important to note that the age at death refers to either 
the actual death of the mouse or the failure of the survival test. On several occasions, mice 
that fail the survival test perished within a day, affirming confidence with these values for 
average age at death. It is also important to note that the differences in average mass 
between the drug and control groups may have been an effect of the random selection of 












Figure 2: A: The drug group in the female cohort (N=32) demonstrated a negative effect on weight gain and 
retention, and accelerated weight loss across the 17 weeks of observation. Despite maintaining a lower average 
mass (Figure 1), the control group more easily put on weight, retained weight, and wasted away slower than 
their drug treated counterparts. Differences between the drug and control groups were not significant at p<.05. 
 
B: The male cohort (N=10) showed smaller differences between drug and control groups, but followed the 
same pattern. The drug group mice were unable to put on and maintain weight as well as the control group for 
the first 8 weeks, however the wasting period (8-15 weeks) showed little difference between drug and control 




















































Drug Treatment Hindered Mass Building and Had Mixed Effects on Wasting Later in Life 
Despite the mass differences mentioned earlier from Figure 1, Figure 2 A and B 
show that the drug group had effects in both the female and male cohorts in terms of mass 
retention and shedding. In Figure 2A, the female cohort is seen building mass for several 
weeks following the start of the drug trial at about 63 days of age – but the drug group lags 
behind the control group in building mass through week 12 of the trial. Following week 12, 
approximately when the mice become symptomatic, the drug group also had an increased 
mass shedding compared to the control group through the end of data collection at week 17. 
These differences were analyzed by two sample T-Test but the resultant p-value was 0.310 – 
indicating that these differences are not significant.   
 In the male cohort shown in Figure 2B, a similar trend can be seen to the female 
cohort – initially the control males are more able to put on mass through week 8. However 
the difference here is that the drug group males lose mass less quickly than control – it 
appears that the drug may help prevent the wasting associated with symptomatic ALS in the 
later stages for the male cohort. The differences were analyzed by two sample T-Test, and 
the resultant p-value was found to be 0.924 – indicating that these differences are also not 
significant.  
 
Drug Treatment Showed No Significant Differences in Motor Ability  
Assessment of motor skills by Rotarod showed similar results for the male and 
female cohorts across the duration of data collection. Figure 3A shows the female cohort’s 
progress, through average trial time, across the 17 weeks of data collection. The drug and 
control group appear to have the same motor skills throughout the 17 weeks, with a slightly 
higher average trial time for an 8-week span in the drug group. Once analyzed by two-sample 
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T-Test, the differences in the female cohort had a p-value of .524, indicating they were not 
significant. 
The male cohort shown in Figure 3B shows a similar trend with slightly more 
volatility as indicated by the sharper curves going up and down for both groups. Unlike in 
the female cohort, the drug group in the male cohort appears to have a higher average trial 
time by up to 20 seconds at the peak, and the drug group appears to sustain the higher 
average for almost the entire duration of the trial. Upon further analysis by two sample T-
Test, the p-value was found to be 0.324, indicating that the differences between groups are 
not significant. However, this may be due to the small sample size (N=10) and it stands to 
reason that these differences may be more striking and closer to significance in a future trial 








Figure 3: A: Average Rotarod trials for female cohort  (N=32) show little difference between drug and control 
groups over 17 week data collection period.  The decline in average Rotarod trial time begins when the mice 
appear to become symptomatic – at 12 weeks (~148 days old) for the female cohort. 
 
B:  Average Rotarod trials for the male cohort  (N=10) shows the drug group with slightly higher average trial 
times over the 15 weeks of data collection, however differences were not significant at p<.05. The decline in 
average Rotarod trial time begins when the mice appear to become symptomatic – at 9.5 weeks (~128 days old) 





















































































































Figure 4: A: Week by week analysis of motor ability trends show the drug group had earlier decay in motor 
abilities through week 8, before both groups began evenly dropping from week 9 onwards. However, there were 
no significant differences (p<.05) in percentage change for female cohort (N=32). 
 
B: Week by week analysis of motor ability trends show that the drug cohort initially decreased strongly until week 
8, after which both the drug and control cohorts decayed at similar rates. However, there were no significant 
difference (p<.05) in percent change for the male cohort (N=10). 
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Figure 4 provides a deeper analysis into how the drug and control groups differed 
across the span of the drug trial with respect to how much the average trial time differed 
from the baseline – the first recorded test. In Figure 4A, there appears to be very little 
difference between the drug group and the control group in terms of average trial time 
percent change from the baseline, a pattern that stays consistent from the beginning to the 
end of the data collection period. Analysis by two-tailed unequal variances T-Test showed a 
p-value of 0.97, indicating that the little differences are in fact not significant.  
In Figure 4B, the male cohort shows a slightly different pattern in average trial time 
percent change from the baseline. The drug group had a greater negative percent change 
than the control group for the first 8 weeks of the drug trial, before the control group began 
having similar negative percent changes for the seven weeks that followed. The differences, 
when analyzed using a two-tailed unequal variances T-Test, had a p-value of 0.49, indicating 
that they were not significant.  
It is also important to note that another means of collecting data that we had 
planned, using the Bioseb Grip Test device, offered no useful data to discriminate between 
drug and control groups. There was a high degree of variability in data produced, much of it 
drawn from factors beyond our control that dealt with the mice – how hard they grasped, 
whether they randomly pulled strongly or weakly, and whether they tried to escape rather 
than hang on to the mesh. The measurements lacked consistency, and the multitude of 






DNA Damage and Proteotoxicity Experiments  
 
 To assess the expression of certain genes that have been implicated in the 
proteotoxicity repair pathways – LSD1 and UBE4B – and the ubiquitin specific protease 
USP7, a series of experiments were devised to damage DNA and impose stress and potential 
proteotoxicity to see how cells deal with the effects. The three-pronged approach for these 
experiments included: inducing DNA damage via a DNA intercalating agent (Doxorubicin), 
transfecting cells with wild type and mutant SOD1, and exposing cells to one and two hours 
of heat shock. The cell types used were: Human Embryonic Kidney 293T Cells (HEK293T), 
Wild Type Human Colon Cancer Cells (HCT116 P53 +/+), P53 Knockout Human Colon 
Cancer Cells (HCT116 P53 -/-), and a Mouse Motor Neuron-like hybrid cell line (NSC34).  
 
I. Doxorubicin DNA Damage 
 In the first leg of the DNA damage and proteotoxicity experiments, only the 
HCT+/+, HCT -/-, and NSC cells were used to assess how pathways worked in the absence 
of p53 and in neural-like cells. Following incubation of 3.0 x 106 cells overnight, cells were 
treated with 4 µl of Doxorubicin for ten minutes before they were lysed to extract protein 
and RNA. The samples were then run on a gel, with the consequent membrane incubated 
with antibodies for USP7, UBE4B, and LSD1, and the loading control of GAPDH.  
Figure 5A shows the results from the Doxorubicin DNA damage portion of the experiment. 
For quantification, the samples were normalized to the loading controls (GAPDH) found at 
the bottom of the figure. For USP7, there is a decrease across each of the cell lines:  a 60% 
decrease in the HCT+/+ cells, an 83% decrease in the HCT -/- cells, and a 23% decrease in 
the NSC34 cells. For UBE4B, there was a similar decrease across all the cell lines: a 15% 
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decrease in HCT +/+ cells, a 28% decrease in HCT -/- cells, and a 13% decrease in NSC 
cells. In LSD1 there was a change in the pattern: a 95% decrease in HCT +/+ cells, a 20% 
decrease in HCT -/- cells, and a 32% decrease in NSC34 cells. For USP7 and UBE4B the 
P53 knockout HCT -/- line had the greatest decrease in protein, but the line had the smallest 
decrease for LSD1.  
 These findings suggest that the decrease in UBE4B and LSD1, which previous 
literature had found to result in a robust increase in clearance of DNA and proteotoxic 
damage, were replicated by this experiment. The reduction in UBE4B, LSD1, and USP7 – 
apparent across all cell lines – suggests that their repression (either at the transcription level, 
or the protein level) is necessary for reducing the toxicity of the damage wrought by the 
DNA intercalating agent. Future directions with this experiment will involve discerning 
whether there is repression at the transcription level through analysis of the RNA present 

































Figure 5: A: Doxorubicin Treatment results – all images taken from same membrane with same exposure.  
USP7: 60% decrease in HCT +/+, 83% decrease in HCT -/-, 23% decrease in NSC34.  
UBE4B: 15% decrease in HCT +/+, 28% decrease in HCT -/-, 13% decrease in NSC34.  
LSD1: 95% decrease in HCT +/+, 20% decrease in HCT -/-, 32% decrease in NSC34.  
 
 
B) Transfection with WT and G85R SOD1 results – all images taken from same membrane with same exposure.  
All percentages reflect G85R increase/decrease over WT transfected cells (control).  
USP7: 40% increase in HEK293T, 45% decrease in HCT +/+, 50% decrease in HCT -/-, 10% decrease in NSC34. 
UBE4B: 42% decrease in HEK293T, 35% decrease in HCT +/+, 21% decrease in HCT -/-, 44% increase in NSC34.  
LSD1: 20% increase in HEK293T, 45% decrease in HCT +/+, 45% decrease in HCT -/-, 4% decrease in NSC34. 
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II. Wild Type and G85R Mutant SOD1 Transfection 
  
For this set of the DNA damage and proteotoxicity experiments, four cell lines 
(HEK294T, HCT +/+, HCT -/-, and NSC34) were used for which 1.5 x 105 cells were 
incubated overnight before transfection with the WT SOD1 and G85R mutant SOD1 the 
following day. The samples, transfected via the Lipofectamine 3000 kit (Life Technologies), 
were then scanned for GFP to identify relative transfection efficiencies – all of which were at 
least 50%. The cells were then lysed to extract protein and RNA. Following the run of 
protein via western blot, the band strength was quantified through normalizing to the 
loading control GAPDH. 
 Figure 5B shows the results from the western blot run using the extracted proteins 
for each of the cell lines. For USP7, there was a slight mix of effects : compared to the WT 
transfected cells,  the SOD1G85R transfected HEK293T cells had an increase in USP7 of 
40%, while the mutant transfected HCT +/+ had a decrease of 45%, the mutant transfected 
HCT -/- had a decrease of 50%, and the mutant transfected NSC34 cells had a decrease in 
USP7 of 10%. For UBE4B, there was a similar pattern to USP7: a 42% decrease in the 
SOD1G85R transfected HEK293T cells compared to the WT transfection, a 35% decrease in 
UBE4B for the HCT+/+ line, a 21% decrease in the HCT -/- line, and a 44% increase in 
UBE4B in the NSC34 cell line. The pattern for LSD1 in the G85R transfected line 
resembled USP7: there was a 20% increase in LSD1 in the G85R transfected HEK203T cell 
line, but a 45% decrease in LSD1 in the mutant transfected HCT+/+ and HCT -/- cell 
lines, and a 4% decrease in LSD1 in the mutant transfected NSC34 cell line.  
The findings in bulk suggest that there is an overall decrease in USP7, UBE4B, and 
LSD1 in the mutant G85R SOD1 transfected cells – affirming results from previous studies 
(including Periz et al. from the same laboratory) signaling that down-regulation of these 
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proteins are necessary measures to improve clearance of protein aggregates. Questions arise 
from the reduction in levels of UBE4B, LSD1, and USP7 that are of similar magnitude for 
the HCT p53 WT and knockout lines, suggesting that the presence of p53 may not play as 
active of a role as hypothesized. Another question comes from the least robust decline of 
these protein levels in the NSC34 cell line, the most clinically relevant for ALS study. Future 
research directions will analyze the RNA samples associated with this experiment, looking 
into whether the proteins were down regulated at the transcriptional level or the protein 
levels within the cell. Another set of experiments will also be necessary to discern the roles 
played by p53.  
 
III. Heat Shock Treatment  
 The final leg of the series of experiments was using the four cell lines for heat shock 
treatments so that we could induce a temperature stress on the cells to see how they would 
counteract it. We incubated 6 x 105 cells overnight, and divided them into three groups – 
control (remains at 37˚C), one-hour heat shock (at 43˚C) and two-hour heat shock (at 43˚C). 
Immediately following the end of the sample’s assigned time in the 43˚C heat, the cells were 
lysed to retrieve protein and RNA. They were then run on a gel, and the quantification of 
their signals was normalized against the loading control GAPDH. This experiment was 
replicated, and the findings discussed below reference both replicates.  
 The results for each of the three target proteins (USP7, UBE4B, and LSD1) were 
consistent with the findings from the other two legs of the experiment in showing decreases 




Heat Shock Brings Steep USP7 Decline Across All Cell Lines 
For USP7, the first replicate of this experiment in HEK293T cells, shown in Figure 
6A, had an overall decrease of 70% in the protein following heat shock – the average 
between two replicate had a decrease of 75% for the one hour heat shock and a decrease of 
65% for the two hour heat shock. The HCT +/+ line, shown in Figure 6B, had a 94% 
decrease overall in USP7 averaged between two replicates, with a 94.5% decrease coming 
with the one hour treatment and a 93% decrease coming with the two hour treatment. The 
HCT -/- line, shown in Figure 7A, had a similar decrease in USP7, at approximately 50% for 
both one and two hour treatments in the averaged across both replicates. The NSC34 cell 
line, shown in Figure 7B, had a robust decrease in USP7 of almost 98% for both the one and 
two hour treatments averaged across both replicates. 
These findings on the decline of USP7 corroborate previous studies mentioned in 
which a decline USP7, a p53 deubiquitinating enzyme, correlates with improved protein 
quality control efficiencies. The protein level declines from control levels in HCT +/+ and 
NSC34 lines were also shown to be significant at the p<.05 level, suggesting that the heat 
shock stress in p53 wild type cells and motor-neuron like cells down regulates USP7 further 
in order to improve protein quality control machinery. Further analysis into the nature of the 
USP7 decline, whether transcriptional or at the protein level, will involve RT and QPCR 






Figure 6: All results are avg. protein signals from two replicates. (*Indicates significance at the p<.05 level) 
A: HEK293T results from heat shock experiment: 
USP7: Compared to control - 75% decrease in 1-hour heat shock, 70% decrease in 2-hour heat shock. 
UBE4B: Compared to control – 50% decrease in 1-hour heat shock, 10% increase in 2-hour heat shock. 
LSD1: Compared to control – 80% decrease in 1-hour heat shock, 50% decrease in 2-hour heat shock. 
 
B: HCT P53 +/+ (WT) results from heat shock experiment:  
USP7: Compared to control – 94.5% decrease in 1-hour heat shock, 93% decrease in 2-hour heat shock. 
UBE4B: Compared to control – 35% decrease in 1-hour heat shock, 6% increase in 2-hour heat shock. 































































































































































Figure 7: All results are avg. protein signals from two replicates. (*Indicates significance at the p<.05 level) 
A: HCT P53 -/- (P53 Knockout) results from heat shock experiment: 
USP7: Compared to control - 54% decrease in 1-hour heat shock, 50% decrease in 2-hour heat shock. 
UBE4B: Compared to control – 33% increase in 1-hour heat shock, 96% increase in 2-hour heat shock. 
LSD1: Compared to control – 80% decrease in 1-hour heat shock, 15% decrease in 2-hour heat shock. 
 
B: NSC34 results from heat shock experiment:  
USP7: Compared to control – 99.3% decrease in 1-hour heat shock, 99% decrease in 2-hour heat shock. 
UBE4B: Compared to control – 96% decrease in 1-hour heat shock, 95% decrease in 2-hour heat shock. 
LSD1: Compared to control – 75% decrease in 1-hour heat shock, 70% decrease in 2-hour heat shock. 
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UBE4B Has a Mixed Decline in Some Heat Shock Affected Cell Types 
 
 In the HEK293T cell line (shown in Figure 6A), the average between two replicate 
had a 50% decrease following the one-hour heat shock treatment, but a 10% increase over 
the control following the two-hour treatment. The average between replicates for the HCT 
+/+ line (Figure 6B) also demonstrated that pattern – a 35% decrease following one hour of 
heat shock, but a 6% increase over the control in the two-hour heat shock treatment. In the 
HCT -/- line (Figure 7A) average between replicates showed an increase of UBE4B up to 
35% following the 1-hour heat shock, and a 96% increase over the control following the 2-
hour heat shock treatment. The NSC34 cell line average between replicates, as shown in 
Figure 7B, had a 96% decrease in UBE4B following the one hour treatment and a 95% 
decrease in UBE4B following the two hour treatment.  
 The decline in UBE4B across most cell lines indicates that the findings from 
previous papers, in which a decline in UBE4B was strongly correlated with improved cell 
damage repair, are supported by these series of experiments. The most robust decline in 
UBE4B compared to the control was in the NSC34 cells, which was found to be significant 
at p<.05. The hypothesis that a decline in UBE4B works in conjunction with other proteins 
in a p53-medaiated protein quality control pathway is supported by this experiment’s 
demonstrated decline in UBE4B because p53 serves as one of the major targets for 
UBE4B’s polyubiquitinating activity. This notion is also supported by the measured increase 
in UBE4B in the HCT p53 knockout cells – suggesting that the absence of p53 as a target 
led to an increase in UBE4B presence within cells. Further studies will also require RNA 
analysis to discern whether the reductions occur transcriptionally or in protein levels, as well 
as more replicates with the p53 WT and Knockout lines to discern the role played by p53 in 
the pathways that involve UBE4B.  
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Heat Shock Treatment Brought Consistent Declines in LSD1 Levels 
 For the HEK293T cells protein levels averaged across both replicates (Figure 6A), 
there was a decrease in LSD1 of 80% in the one-hour heat shock treatment and a decrease 
of 50% in the two-hour treatment. In the HCT +/+ line, as shown in Figure 6B, there was a 
70% reduction in LSD1 following the one hour treatment, and a 30% reduction following 
the two hour treatment. The HCT -/- line, shown in Figure 7A, had an 80% reduction in the 
one hour treatment, followed by a lesser 15% reduction in the two hour heat shock 
treatment. For the NSC34 cell line, shown in Figure 7B, there was a decrease in LSD1 of 
75% following the one hour treatment and a 70% reduction following the two hour 
treatment.   
 The consistent decline in LSD1 with the one and two hour heat shock treatments 
offers support to previous literature detailing how stressors affecting macromolecules (such 
as DNA and protein) lead to a decline in LSD1 as the protein quality control mechanisms 
come into full swing. The LSD1 decline in NSC34 cells, much like the other target proteins 
in the study, was significant at the p<.05 level, suggesting that in neural-like cells the 
proposed protein quality control pathways that suppress neurotoxic protein aggregation 
(Periz et al., 2015) are active.  Taken together with the decline in UBE4B, the heat shock 
experiment adds to the body of understanding of the proposed SUNS pathway by 







 With the positive results of the Tenovin-1 drug in cell culture knocking down SOD1 
aggregation, the natural next step was to test the drug in vivo. With the drug trial in G93A 
mice, we looked the effects of potentially knocking down mutant SOD1 aggregation through 
the lens of motor ability and mass retention – both of which decrease drastically with 
progression of disease. The data for motor skills, gleaned from performance over weeks on 
the Rotarod device, indicated that there was no significant difference between the drug and 
control groups in either the male or female cohort. Additionally, the mass building of mice 
seemed to fall behind in the drug group, while the wasting common with more advanced 
degree progression seemed to accelerate with the drug treatment – though all differences 
were also shown to be not statistically significant. While statistical significance may fall 
victim to the small sample sizes (N=32 for females, N=10 for males), there may have also 
been an issue with beginning mice on the trial too late in age for the drug to have a 
substantial effect on survival and motor skills.  
 With the potential for optimizing this experiment for the future with younger mice at 
the start, leaving more time for qualitative data collection after 15 weeks of drug injections, 
there is promise for positive results. Additionally, this approach of using P53 activating drugs 
for delaying or potentially subverting neurodegenerative disease caused by misfolded protein 
aggregation represents an active area of research in a direction that has only recently been 
explored in basic science, medicine, and public health.  
 With the experiments that induced DNA damaging stress and proteotoxicity, there is 
an addition to the body of knowledge on which target proteins found in elevated or 
repressed quantities – especially as consistent patterns across cell lines. With the knowledge 
that USP7, UBE4B, and LSD1 are all found in reduced quantities in cells that have suffered 
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DNA damage, Heat shock damage, or are dealing with mutant SOD1 aggregation, there is 
greater support for the notion that they may work synergistically as hypothesized in a p53-
mediated protein quality control pathway. The nature of the results in the varied cell types – 
from those used as controls (HEK293T), to those used to discern the impact of p53’s 
presence (HCT +/+, HCT -/-), to those framing the issue in the context of relevant cells to 
ALS study (NSC34) – suggest that the results are replicable and demonstrate the need for a 
series of experiments to detail the impacts of the target proteins in a potential mechanism 
dealing with stressors.  
 Through elucidating some of the pieces in place that form part of greater 
mechanisms that deal with proteotoxicity, we can uncover more therapeutic targets that 
would stymie and/or prevent progression of a multitude of neurodegenerative diseases. 
Through better understanding of how proteins like UBE4B, LSD1, and USP7 work in 
conjunction with the “guardian of the genome” P53, it stands to reason that more 
developments down these lanes hold great promise for discerning the causes of 
malfunctioning protein quality control that cause a variety of diseases from amyotrophic 
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